We would love to hear your thoughts about our site and services, please take our survey here.
Sum-of-parts analysis reveals that GSK is significantly undervalued and its true value is likely to be unlocked by its consumer healthcare JV and subsequent spin-off.
The strategy aligns well with GSK's priority to build innovation, performance and trust.
5.4% yield provides a comfortable waiting fee for long-term investors.
https://seekingalpha.com/article/4391790-taking-look-special-situation-glaxosmithkline?utm_medium=email&utm_source=seeking_alpha#alt1&mail_subject=gsk-taking-a-look-at-the-special-situation-with-glaxosmithkline&utm_campaign=rta-stock-article&utm_content=link-0
GlaxoSmithKline Starts Phase 3 Trial Of RSV Maternal Candidate Vaccine
(Alliance News) - GlaxoSmithKline PLC on Monday said patient dosing has started in a phase three trial investigating the safety and efficacy of its Respiratory Syncytial Virus candidate vaccine for maternal immunisation.
GSK said it is estimated that every year, 33 million cases of RSV occur in children less than 5 years old. RSA is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants and, currently, there is no vaccine available for RSV.
A phase 1/2 study showed the candidate vaccine was well-tolerated and able to "rapidly boost" pre-existing immunity in non-pregnant women, leading to a high level of protecting neutralising antibodies. First data in pregnant women are expected to be presented in 2021.
"RSV burden is high amongst young infants – a vaccine which protects them from birth would represent significant progress in addressing the burden of RSV, preventing infant illness and families' distress, as well as reducing the associated burden for society," said Emmanuel Hanon, senior vice president and head of Vaccines R&D for GSK.
AstraZeneca poised to deliver first batches of COVID-19 vaccine to London hospitals next week
Oct. 26, 2020 9:20 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor
Proactive reports that AstraZeneca (NASDAQ:AZN) will be delivering the first batches of its COVID-19 vaccine, currently dubbed AZD1222, to London hospitals as soon as next week.
A major London hospital trust was told to put other clinical trials on hold so it could prepare to vaccinate health workers the Sun reported.
Health Secretary Matt Han**** said vaccinating health workers was not his "central expectation" although he did not rule it out. In a interview with the BBC, he said, “We want to be ready in case everything goes perfectly but it’s not my central expectation that we will be doing that this year, but the programme is progressing well. On my central expectation, I would expect the bulk of the rollout to be in the first half of next year.”
Last week, a Bristol University study confirmed that the vaccine builds strong immunity to the coronavirus as hoped.
Shares up 1% premarket on average volume. Shares are up 2% on the London Stock Exchange.
Johnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant
https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/
From Fool board:
It isn't publicly known exactly how many patients have received AZD1222, but investors can get some clues from Moderna (NASDAQ:MRNA), which had enrolled 21,411 participants in its late-stage coronavirus vaccine clinical trial as of Friday. Meanwhile, vaccine collaborators Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) had enrolled 25,189 participants as of an update on Monday.
With that many people enrolled in coronavirus clinical trials, it's highly likely that one of the participants would develop a serious illness unrelated to the vaccination. Of course, proving that it's unrelated could be challenging and might only be possible by testing AZD122 on more participants. If the adverse event only occurs in one out of 50,000 participants, it's either unrelated or a side effect with such a low incidence level that it's a tolerable issue.
I'll start with a disclaimer.
I do not and never have owned shares in this company, but what an opportunity I I was completely unaware of five years ago.
If I had been foresighted enough to buy some then I would now sell SOME (not all) to recover my original investment. That way by banking some profit the shares that I have left would "owe me nothing"
I have do this with my Amazon shares that were originally bought at $280/share and still hold the residue
Best of luck to you all & I wish I had bought a couple of hundred when they were only £5/share.
Longer post here:
https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/
"Standard review process triggered a pause to vaccination to allow review of safety data," says an AstraZeneca (NYSE:AZN) spokesperson after a Phase 3 study of its COVID-19 vaccine (developed with University of Oxford) has been put on hold across the U.S. after a suspected serious adverse reaction on a U.K. participant.
It is not clear whether a regulatory agency ordered the halt or if the company itself initiated the action.
One source says the hold was placed out of "an abundance of caution." Another source says the issue is impacting other AZN vaccine trials underway, as well as trials being done by other manufacturers.
Shares are down 8% in after hours action.
Your bemoaning the imagined manipulation of the UK stock market isn't going to change anything. So either except that or take your money out and buy into the US market or put it somewhere else.
If you want solid reliable US Pharma stocks then look at JnJ, or Abbot Labs or Abbvie. Those are not recommendations
by the way, just companies that I happen to be invested in.
DYOR
AstraZeneca PLC late on Monday said it has expanded US trials of its Covid-19 vaccine and the drugmaker added that its applications for regulatory approvals across the globe will meet "stringent" requirements.
The US probe of the AZD1222 vaccine will see trial centres recruit up to 30,000 adults from a variety of ethnic groups and will also include those with underlying medical conditions which leave them more exposed to the SARS-CoV-2 virus.
"Participants are being randomised to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine than the saline control. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants," Astra said.
In July, AstraZeneca ported encouraging interim results from a trial of the vaccine, being developed alongside Oxford University.
The much-anticipated findings showed that a single dose of AZD1222 resulted in a four-fold increase in antibodies fighting SARS-CoV-2, the virus strain which causes Covid-19.
Also on Monday, Astra said outlined its "commitment to the highest safety standards and to broad and equitable access around the world" for its Covid-19 vaccine.
"At the heart of AstraZeneca's core values is to 'follow the science' and adhere to the highest scientific and clinical standards, making the safety and efficacy of the vaccine of paramount importance. The company's submissions for market authorisation will meet the stringent requirements established by regulators everywhere around the world," the company said.
The statement came after reports on Sunday raised the possibility that a future vaccine against the coronavirus might be given emergency approval in the US before the end of trials designed to ensure its safety and effectiveness.
A request for such extraordinary approval would have to come from the vaccine developer, Stephen Hahn - the head of the US Food & Drug Administration - told the Financial Times.
"If they do that before the end of Phase Three," which involves large-scale human testing, "we may find that appropriate. We may find that inappropriate, we will make a determination."
But Hahn insisted he was not acting under pressure from President Donald Trump, who has been pushing hard for a vaccine, saying one might be ready before US elections November 3.
US President Donald Trump will announce on Thursday a deal for 150 million rapid COVID-19 tests as he eyes a return to normal life ahead of November’s elections, White House officials told AFP.
The purchase from Abbott Laboratories is part of a $750 million deal with the company, a senior administration official said.
AZN market capitalisation is about £112 billion so "manipulation" is unlikely.
All vaccine sales to date have not been bookable sales just promises to but IF IT WORKS!
I'm putting these minor SP movements down to "noise", but then what do I know?
I can not comment about Moderna, but as to the rest of your post I will say that over the last few years I have been heavily investing is US shares especially in the technology sector; principally the Pharmaceuticals, Biotechnology & Life Sciences,Health Care Equipment & Services, Software & Services sectors.
This is not a recommendation to follow suit and DYOR
Astrazeneca rejects Trump shortcut for coronavirus vaccine
https://www.thetimes.co.uk/edition/news/astrazeneca-rejects-trump-shortcut-for-coronavirus-vaccine-9lt9nxf7r